Objective To demonstrate variations in HbA1C (glycosylated haemoglobin) levels between two paediatric cohorts with different approach in diabetes management in blood glucose monitoring (routine and intense) and insulin administration. Design A follow up cohort study of 34 children and adolescents in a large district hospital with diagnosis of Type 1 diabetes between 2005 and 2011. Results In the first group (G1=14), without intensive blood sugar monitoring, mean HbA1Cpost diagnosis was 8.67% (95% CI 7.87–9.48%).11 out of 14(79%) of them had HbA1C above target level (7.5%). In the second group (G2=20) with intensive monitoring, mean HbA1Cpost diagnosis was 7.87% (95% CI 7.29–8.44%). 12 out of 20 (60%) had HbA1C above target level (7.5%) Table 1 G1a/b: Group without intensive initial monitoring’2005/12 G2a/b: Group with intensive initial monitoring’2011/12 Abstract PO-0068 Table 1 Mean HbA post diagnosis quarter (95% CI) HbA >7.5% (Numbers/%) Reduction of HbA levels achieved (%) G1a 8.67(7.87–9.48) 11(79) 21 G1b 10.45(9.10–11.81) 13(93) 7 G2a 7.87(7.29–8.44) 12(60) 40 G2b 7.81(7.33–8.29) 13(65) 35 Abstract PO-0068 Table 2 HbA trends (%) 95% CI (%) G1(a vs. b) +1.78 0.24–3.32 G2(a vs. b) -0.06 0.52–0.40 CI-Confidence Interval Conclusions No significant difference of HbA in two groups post diagnosis; mean HbA1C level (p = 0.082). Comparing the changes over time in the two groups, an increase of HbA1C of 1.78 (Table2) percentage points in G1 (without intensive monitoring) was significantly greater than the decrease of 0.06 percentage points in G2 (p = 0.008). Discussion Intensive initial management of type 1 Diabetes can significantly reduce future HbA1C. We aim to follow G2 over next 5 years to establish that an improved metabolic memorycould reduce HbA1C levels over longer periods.
Background: Diabetes mellitus is an emerging non communicable, life style disease & the use of anti-diabetics has been increasing. Adverse drug reactions (ADRs) are well known to occur with any class of drugs when used in normal doses for the management of diseases. Anti-diabetic agents are no exception to this. The study of ADRs is the concern of the field known as pharmacovigilance. The objective of the present study was to analyze and describe the patterns of adverse events associated with the use of oral Anti-diabetic agentsMethods: A hospital based prospective observational study at Hi-Tech Medical College and Hospital, Bhubaneswar, Orissa. Convenience samples of 266 adult patients, prescribed with oral anti-diabetic agents from October 2016 to November 2018 were selected, out of which 74 patients developed ADRs. Data collected from available prescriptions. The severity assessment is done using the Hartwig and Siegal scale and preventability assessment using modified Schumock and Thornton is done.Results: Study suggests that female predominance in 41 (55.40%) patients with maximum cases of 43.24% in age group of 61-70 years age group. Maximum ADRs reported related to endocrine system seen in 36 (48.67%) patient population. Sulfonylureas 38 (51.35%) shows the largest numbers of ADR. The maximum ADRs reported were probable (56.73%). The severity assessment using the Hartwig and Siegal scale indicated that the majority of the ADRs were 63 (81.63%) as mild cases respectively.Conclusions: This study has provided evidence of monitoring and detecting ADRs and their management through therapeutic interventions which is beneficial in the better patient outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.